In the case of William R. Warner & Company v. Eli Lilly & Company, 1923, the U.S Supreme Court ruled in favor of Eli Lilly and upheld their patent rights for a medicine called "Elixir Sulfanilamide". The court found that William R. Warner & Co had infringed on this patent by producing a similar product without permission from Eli Lilly. This decision was significant as it reinforced the importance of intellectual property rights within pharmaceutical industry and set precedent for future cases involving drug patents.

In the dissenting opinion for William R. Warner & Company v. Eli Lilly & Company, it was argued that the majority's decision to uphold a patent on a medical compound known as "adrenalin" was flawed because it granted monopoly rights over a naturally occurring substance. The dissenting justices believed that such substances should not be subject to patents, regardless of whether they had been isolated or purified by human intervention. They contended that allowing such patents would stifle competition and innovation in the pharmaceutical industry, as companies could prevent others from using natural substances simply by being the first to isolate them. Furthermore, they expressed concern about potential abuses of this power and its impact on public health and welfare.